Use of CytoSorb® hemoadsorption column during prolonged cardiopulmonary bypass in complex cardiac surgery patient.

Autor: Alarie M; Kingston Health Sciences Centre, Kingston, ON, Canada. marianne.alarie@kingstonhsc.ca., Savelberg M; Kingston Health Sciences Centre, Kingston, ON, Canada., Vautour D; Kingston Health Sciences Centre, Kingston, ON, Canada., Ribeiro IB; Kingston Health Sciences Centre, Kingston, ON, Canada.
Jazyk: angličtina
Zdroj: Journal of cardiothoracic surgery [J Cardiothorac Surg] 2022 Jul 07; Vol. 17 (1), pp. 172. Date of Electronic Publication: 2022 Jul 07.
DOI: 10.1186/s13019-022-01922-7
Abstrakt: Background: Complex cardiac surgery and prolonged cardiopulmonary bypass are associated with significant activation of the systemic inflammatory response system. Pro-inflammatory cytokines, oxygen free radicals and complement activation products contribute to postoperative complications and multiorgan injury. CytoSorb® hemoadsorption therapy has been suggested to alleviate the hyperinflammatory response triggered by cardiopulmonary bypass during cardiac surgery.
Case Presentation: We describe the use of CytoSorb® hemoadsorption therapy in a 61-year-old male presenting for aortic valve replacement, mitral valve replacement, tricuspid valve repair, coronary artery bypass grafting and left atrial appendage clip.
Conclusion: We were able to demonstrate that CytoSorb® use during cardiopulmonary bypass may be a safe and feasible adjunct therapy that may contribute to improved postoperative outcomes in a patient with complex cardiac disease.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje